Virological responses of pegylated interferon alpha-2a treatment in hemodialysis patients infected with hepatitis C
CLINICAL AND EXPERIMENTAL NEPHROLOGY, vol.17, no.1, pp.115-119, 2013 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 17 Issue: 1
- Publication Date: 2013
- Doi Number: 10.1007/s10157-012-0663-x
- Journal Name: CLINICAL AND EXPERIMENTAL NEPHROLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.115-119
- Keywords: Hepatitis C, Interferon, Hemodialysis patients
- Dokuz Eylül University Affiliated: No
Abstract
Hepatitis C is the most frequently encountered hepatic disease in dialysis patients. Data related to pegylated interferon alfa-2a (Peg-IFN-alpha-2a) use in hemodialysis patients with hepatitis C virus (HCV) are limited. The aim of this study was to evaluate the efficacy of Peg-IFN-alpha-2a among these patients.